ReviewTranslational neurodegeneration2016
The biomarkers of immune dysregulation and inflammation response in Parkinson disease.
Review in Translational neurodegeneration, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Neutrophil to lymphocyte ratio in parkinson's disease: a systematic review and meta-analysis.BMC neurology · 2023Pooled it
- Functional alterations of peripheral blood CD4+ T lymphocyte subsets in patients with Parkinson disease: A review.Medicine · 2026Review
- Plasma expression levels of microRNA-101 are downregulated in patients with Parkinson's disease.BMC research notes · 2025Article
- Infections in the Etiology of Parkinson's Disease and Synucleinopathies: A Renewed Perspective, Mechanistic Insights, and Therapeutic Implications.Journal of Parkinson's disease · 2024Review
- Article
- Sequence Variants in PSMB8/PSMB9 Immunoproteasome Genes and Risk of Urothelial Bladder Carcinoma.Cureus · 2023Article
- Overview of the Role of Vanillin in Neurodegenerative Diseases and Neuropathophysiological Conditions.International journal of molecular sciences · 2023Review
- Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson's disease.Molecular therapy. Nucleic acids · 2021Article
- Article
- MicroRNA-101 Regulates 6-Hydroxydopamine-Induced Cell Death by Targeting Suppressor/Enhancer Lin-12-Like in SH-SY5Y Cells.Frontiers in molecular neuroscience · 2021Article
- Inflammasome and Cognitive Symptoms in Human Diseases: Biological Evidence from Experimental Research.International journal of molecular sciences · 2020Review
- Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms.BMC neurology · 2020Article
- Molecular Mechanisms of Glutamate Toxicity in Parkinson's Disease.Frontiers in neuroscience · 2020Review
- Paeonol attenuates inflammation by targeting HMGB1 through upregulating miR-339-5p.Scientific reports · 2019Article
- Differential proteomic analysis of serum exosomes reveals alterations in progression of Parkinson disease.Medicine · 2019Article
- Aging, rather than Parkinson's disease, affects the responsiveness of PBMCs to the immunosuppression of bone marrow mesenchymal stem cells.Molecular medicine reports · 2019Article
- Neuroprotective Effect of Optimized Yinxieling Formula in 6-OHDA-Induced Chronic Model of Parkinson's Disease through the Inflammation Pathway.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Dysregulated Long Non-coding RNAs in Parkinson's Disease Contribute to the Apoptosis of Human Neuroblastoma Cells.Frontiers in neuroscience · 2019Article
- Diagnostic biomarkers for Parkinson's disease at a glance: where are we?Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is referring to the multi-systemic α-synucleinopathy with Lewy bodies deposited in midbrain. In ageing, the environmental and genetic factors work together and overactive major histocompatibility complex pathway to regulate immune reactions in central nerve system which resulting in neural degeneration, especially in dopaminergic neurons. As a series of biomarkers, the human leukocyte antigen genes with its related proteomics play cortical roles on the antigen presentation of major histocompatibility complex molecules to stimulate the differentiation of T lymphocytes and i-proteasome activities under their immune response to the PD-related environmental alteration and genetic variation. Furthermore, dopaminergic drugs change the biological characteristic of T lymphatic cells, affect the α-synuclein presentation pathway, and inhibit T lymphatic cells to release cytotoxicity in PD development. Taking together, the serum inflammatory factors and blood T cells are involved in the immune dysregulation of PD and inspected as the potential clinic biomarkers for PD prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.